Divestment gains push Orchid back to net profit
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticals has reported a consolidated net profit of Rs3.39 billion ($72 million) for the year ended 31 March 2010, as against a net loss of Rs490 million in the previous fiscal year. The move back into the black was largely on account of gains from the sale of its generic injectables finished dosage business to Hospira.